Press Releases

 
Press Releases
  Date Title View
Aug 10, 2016
LEXINGTON, MA -- (Marketwired) -- 08/10/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported second quarter financial results and provided a corporate update. "We are extremely pleased with our progress through ...
PDF
Aug 9, 2016
LEXINGTON, MA -- (Marketwired) -- 08/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported positive data from a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatol...
PDF
Aug 8, 2016
LEXINGTON, MA -- (Marketwired) -- 08/08/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that, on Tuesday, August 9, 2016, prior to the market open, it will report the results of a randomized, parallel-group, double-b...
PDF
Aug 4, 2016
LEXINGTON, MA -- (Marketwired) -- 08/04/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Canaccord Genuity Annual Growth Conference on...
PDF
Aug 3, 2016
LEXINGTON, MA -- (Marketwired) -- 08/03/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the second quarter ended June 30, 2016 on Wednesday, August 10, 2016, prior to the ...
PDF
Jun 7, 2016
LEXINGTON, MA -- (Marketwired) -- 06/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra's randomized, parallel-group, double-masked, vehicle-controlled Phase II c...
PDF
Jun 1, 2016
LEXINGTON, MA -- (Marketwired) -- 06/01/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,760,000 shares of its common stock, includi...
PDF
May 26, 2016
LEXINGTON, MA -- (Marketwired) -- 05/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the pricing of an underwritten public offering of 2,400,000 shares of its common stock at a price to the public of $5.00 per sha...
PDF
May 25, 2016
LEXINGTON, MA -- (Marketwired) -- 05/25/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to mark...
PDF
May 9, 2016
LEXINGTON, MA -- (Marketwired) -- 05/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported that a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase II clinical trial of topical ocu...
PDF
Page: FirstPrevious
3
... NextLast